Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
NCT ID: NCT03062917
Last Updated: 2019-11-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
152 participants
INTERVENTIONAL
2015-10-02
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Innate Immune Responses in Infants With Bronchiolitis
NCT01159795
Nasal Suction in Infants With Bronchiolitis Using a NoseFrida vs. Bulb Syringe
NCT04599101
The Genetics of Respiratory Failure in Bronchiolitis
NCT01271491
National Observatory of Children Hospitalized for Bronchiolitis
NCT06112132
Suctioning of NOse Therapy in Bronchiolitis
NCT03361371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We would like to use these SAMs to take MLF samples from the nasal and bronchial mucosal surfaces to see if these novel techniques can overcome the problems with current sampling methods. We plan to use these absorption techniques to measure RSV viral load. We also aim to look at the immune response in terms of the anti-viral interferon response (IFN-γ, IFN-λ, IFN-α2a, IP10, ITAC). In therapeutic studies in the future, it may be possible to document levels of drug (pharmacokinetics) in nasal MLF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Emergency Department
Babies with suspected respiratory tract infection (RTI) in the ED
Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Paediatric Wards
Babies with diagnosed RSV infection admitted to paediatric wards
Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Paediatric Intensive Care
Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Health Controls
Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Controls in Paediatric Intensive Care
Babies without RSV infection but requiring mechanical ventilation in PICU
Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presentation to the Emergency Department with any upper respiratory tract infection (URTI) in the RSV season (Oct-March).
OR • Documented RSV infection, admitted to the paediatric wards at St Mary's Hospital.
* Hospitalised Infants admitted to the PICU at St. Mary's Hospital, aged 2 weeks-24 months with documented RSV infection (by rapid test and/or PCR).
* Infants of weight \>2kg.
* On a conventional ventilator with an Endotracheal Tube (ETT) of \>3.0mmm diameter
• Babies, aged 2 weeks-24 months, attending routine outpatient appointments or undergoing elective surgical procedures.
* Infants aged 2 weeks-24 months.
* Infants ventilated on the PICU for any condition
* Confirmed RSV negative by PCR of respiratory tract samples
Exclusion Criteria
* Bilateral indwelling nasal catheters or local nasal pathology preventing access for nasal sampling.
* Bleeding disorders.
* The baby is taking part in another interventional study.
* The parents or guardians not able to sign the informed consent from due to limited English or comprehension despite the use of independent interpreter services.
* Limited life expectancy of the baby,
Group 3
* Any local or systemic factor that would influence the safety of nasal sampling.
* Bilateral nasal catheters or local nasal pathology preventing access for nasal sampling.
* The baby is taking part in another interventional study.
* Prematurity - corrected gestational age \<36 weeks, weight \<2kg
* Significant hypoxia or instability precluding ventilator disconnection
* ETT \< 3mm internal diameter
* Transcutaneous oxygen saturation of \<95% on 60% oxygen
* Risk of bleeding
* Pneumothorax
* Infants receiving oral corticosteroid therapy at any time in past month
* Parents or guardians not able to sign informed consent from due to limited English or understanding despite the use of independent interpreter services.
* Limited life expectancy or a decision to limit management,
* Any respiratory symptoms
* All other exclusion are the same as Groups 1 and 2
Control Group 2
* All exclusions are the same as Group 3
* In addition - any concern about raised intracranial pressure
2 Weeks
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pulmocide Ltd
INDUSTRY
Imperial College Healthcare NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imperial College NHS Healthcare Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15/WM/0343
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.